Fig. 4From: The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus(Reprinted with permission from Neal [16])The CANVAS Program: CV death, nonfatal myocardial infarction, or nonfatal stroke. CV, cardiovascular; CI, confidence intervalBack to article page